PolyPid Ltd.
PYPDPolyPid Ltd. in brief
PolyPid Ltd. is a listed company in the Biotechnology industry, based in Israel. Its market value was $103 M on 1 August 2026, which makes it the 18,597th largest listed company in the world and the 199th largest in Israel on this site. It employs about 59 people and Dikla Czaczkes Akselbrad is its chief executive. Its shares trade under the symbol PYPD (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About PolyPid Ltd.
PolyPid, BonyPid, Bacfenssi, Baczenssi, Opzifend, Ssisurg, Elyfssi and Bacyssio are our proprietary trademarks. These trademarks are important to our business. Although we have omitted the “®” and “TM” trademark designations for such marks in this annual report on Form 20-F, all rights to such trademarks and service marks are nevertheless reserved.
The risk factors described below are a summary of the principal risk factors associated with an investment in us. These are not the only risks we face. You should carefully consider these risk factors, together with the risk factors set forth in Item 3D. of this annual report on Form 20-F and the other reports and documents filed by us with U.S. Securities and Exchange Commission, or the SEC.
From the company's annual report filed with the US SEC: read the report
PolyPid Ltd. timeline
- 2014
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2020
- 🔔· approximateInitial public offering on Nasdaq
Events of PolyPid Ltd. from SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Israel: #172 (Jan 2021) · #280 (Jan 2022) · #398 (Dec 2022) · #440 (Jul 2023) · #436 (Jan 2024) · #35 (Mar 2026) · #200 (Aug 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 9.4×
- Free cash flow yield
- -27.2%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -311.5%
- Liabilities / assets
- 50.8%
- Net debt
- $-15M
- Profit per employee
- $-579 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-33M | $-34M | — |
| Dec 2024 | — | — | $-28M | $-29M | — |
| Dec 2023 | — | — | $-23M | $-24M | — |
| Dec 2022 | — | — | $-39M | $-40M | — |
| Dec 2021 | — | — | $-43M | $-43M | — |
| Dec 2020 | — | — | $-26M | $-37M | — |
| Dec 2019 | — | — | $-19M | $-7M | — |
| Dec 2018 | — | — | $-18M | $6M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-28M | $0M | $-28M | $2.09 | — |
| Dec 2024 | $-22M | $0M | $-22M | $4.91 | — |
| Dec 2023 | $-17M | $0M | $-17M | $16.93 | — |
| Dec 2022 | $-34M | $2M | $-36M | $61.09 | — |
| Dec 2021 | $-32M | $3M | $-35M | $68.27 | — |
| Dec 2020 | $-22M | $1M | $-22M | $4.48 | — |
| Dec 2019 | $-17M | $1M | $-18M | $23.69 | — |
| Dec 2018 | $-17M | $3M | $-20M | $0.86 | — |
SEC filings
- Nov 12, 20266-KReport of foreign issuer
- Oct 28, 20266-KReport of foreign issuer
- Oct 1, 20266-KReport of foreign issuer
- Oct 1, 20266-KReport of foreign issuer
- Aug 12, 20266-KReport of foreign issuer
- Aug 12, 20266-KReport of foreign issuer
- Jul 29, 20266-KReport of foreign issuer
- Jul 21, 20266-KReport of foreign issuer
- Jul 15, 20266-KReport of foreign issuer
- Jun 10, 20266-KReport of foreign issuer
- Jun 1, 20266-KReport of foreign issuer
- May 13, 20266-KReport of foreign issuer
Official filings of PolyPid Ltd. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-33 M
- Net income
- $-34 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $22 M
- Total liabilities
- $11 M
- Total equity
- $11 M
As of December-2025
Top 25 institutional investors in PolyPid Ltd.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | AIGH Capital Management LLC | 1,246,741 | -258,000 (-17.15%) | 5.18% | $7 M | Nov 2, 2026 |
| 2 | DAFNA Capital Management LLC | 207,900 | 0 (0.00%) | 0.86% | $1 M | Nov 16, 2026 |
| 3 | Marshall Wace, LLP | 199,745 | +84,731 (+73.67%) | 0.83% | $1 M | Nov 13, 2026 |
| 4 | Rosalind Advisors, Inc. | 177,011 | -212,444 (-54.55%) | 0.74% | $1 M | Nov 16, 2026 |
| 5 | Two Sigma Investments, LP | 145,022 | New | 0.60% | $1 M | Nov 16, 2026 |
| 6 | Renaissance Technologies LLC | 131,800 | +15,181 (+13.02%) | 0.55% | $1 M | Nov 12, 2026 |
| 7 | ADAR1 Capital Management, LLC | 103,950 | 0 (0.00%) | 0.43% | $1 M | Nov 16, 2026 |
| 8 | Jane Street Group, LLC | 98,221 | +15,095 (+18.16%) | 0.41% | $1 M | Nov 12, 2026 |
| 9 | Susquehanna International Group, LLP | 80,454 | +40,427 (+101.00%) | 0.33% | $0 M | Nov 16, 2026 |
| 10 | Citadel Advisors LLC | 53,781 | +11,499 (+27.20%) | 0.22% | $0 M | Nov 16, 2026 |
| 11 | Lumbard & Kellner, LLC | 38,200 | 0 (0.00%) | 0.16% | $0 M | Nov 12, 2026 |
| 12 | HRT Financial LP | 24,960 | -12,344 (-33.09%) | 0.10% | $0 M | Nov 13, 2026 |
| 13 | B. Riley Wealth Advisors, Inc. | 20,085 | +4,955 (+32.75%) | 0.08% | $0 M | Oct 13, 2026 |
| 14 | HighTower Advisors, LLC | 13,000 | +2,000 (+18.18%) | 0.05% | $0 M | Nov 10, 2026 |
| 15 | Simplex Trading, LLC | 8,118 | +7,655 (+1653.35%) | 0.03% | $0 M | Nov 4, 2026 |
| 16 | Steward Partners Investment Advisory, LLC | 7,346 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 17 | Northwestern Mutual Wealth Management Co | 3,968 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 18 | Osaic Holdings, Inc. | 467 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 19 | Jpmorgan Chase & Co | 345 | +297 (+618.75%) | 0.00% | $0 M | Nov 12, 2026 |
| 20 | Morgan Stanley | 259 | -122,877 (-99.79%) | 0.00% | $0 M | Nov 13, 2026 |
| 21 | Group One Trading LLC | 200 | -130 (-39.39%) | 0.00% | $0 M | Nov 10, 2026 |
| 22 | Assetmark, Inc | 42 | New | 0.00% | $0 M | Oct 21, 2026 |
| 23 | Rockefeller Capital Management L.P. | 33 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 24 | Caitong International Asset Management Co., Ltd | 6 | -59 (-90.77%) | 0.00% | $0 M | Oct 29, 2026 |
| 25 | SBI Securities Co., Ltd. | 1 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
Markets and events: PolyPid Ltd.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2024-12-24 14:33 UTC, code LUDP, resumed 14:43 UTC
Fails to deliver
- : 1,037 shares at $4.88
- : 1,998 shares at $4.83
- : 1,910 shares at $5.02
- : 503 shares at $4.90
- : 1,675 shares at $5.13
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
PolyPid Ltd. scorecard#
Passes 2 of the 8 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year2.09 vs 4.91Diluted EPS 2.09 in fiscal 2025 against 4.91 the year before (report's currency).
- ✓Net income higher than five years earlier-$34 M-$34 M in fiscal 2025 against -$37 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$34 MNet income -$34 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-366.4%-366.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities2.0×Current ratio 1.97 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year176.5%Diluted shares up 176.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
PolyPid Ltd.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Research and development | 24+4.4%— | 23+41.3%— | 16−42.3%— | 28−8.4%— | 31+80.2%— | 17+20.4%— | 14+12.2%— | 13—— | |
| General and administrative | 7.2+68.1%— | 4.3−22.6%— | 5.5−31.0%— | 8.0−16.6%— | 9.6+24.7%— | 7.7+115%— | 3.6−31.8%— | 5.3—— | |
| Operating income | −33—— | −28—— | −23—— | −39—— | −43—— | −26—— | −19—— | −18—— | |
| Interest and finance income | 0.5+17.0%— | 0.4−19.3%— | 0.5+105%— | 0.3−42.9%— | 0.5−1.3%— | 0.5+690%— | 0.1−52.4%— | 0.1—— | |
| Other non-operating income (expense) | −0.7—— | −1.0—— | −0.9—— | −0.5−199%— | 0.5—— | −11−191%— | 12−52.0%— | 24—— | |
| Income before tax | −34—— | −29—— | −24—— | −39—— | −43—— | — | — | — | |
| Income tax | 0.0−88.1%— | 0.0−39.1%— | 0.1−46.5%— | 0.1—— | — | — | — | — | |
| Net income including minority interests | — | — | — | −40—— | −43—— | −37r37—— | −6.9r6.9—— | −5.9—— | |
| Net income attributable to shareholders | −34—— | −29—— | −24—— | −40—— | −43—— | −37—— | −6.9−217%— | 5.9—— | |
| Earnings per share, basic | 2.09−57.4%— | 4.91−71.1%— | 16.99−72.2%— | 61.09r2.04−10.5%— | 68.27r2.28+1424%— | 4.48−81.1%— | 23.69—— | -0.16—— | |
| Earnings per share, diluted | 2.09−57.4%— | 4.91−71.0%— | 16.93−72.3%— | 61.09r2.04−10.5%— | 68.27r2.28+1424%— | 4.48−81.1%— | 23.69+2655%— | 0.86—— | |
| Shares, weighted average (basic) | 16+177%— | 5.9+321%— | 1.4+117%— | 0.6r19+3.8%— | 0.6r19−93.5%— | 9.6+1604%— | 0.6+0.2%— | 0.6—— | |
| Shares, weighted average (diluted) | 16+177%— | 5.9+316%— | 1.4+119%— | 0.6r19+3.8%— | 0.6r19−93.5%— | 9.6+1604%— | 0.6−8.3%— | 0.6—— | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 6.4−59.1%28.7% | 16+195%62.0% | 5.3−37.9%34.5% | 8.6−12.9%32.9% | 9.8+127%22.2% | 4.3+10.1%5.7% | 3.9−49.5%11.6% | 7.8—— | |
| Other current assets | 0.0−89.9%0.1% | 0.3r0.8−41.5%1.1% | 0.5−57.9%3.0% | 1.1—4.2% | — | — | — | — | |
| Current assets | 15−8.1%68.3% | 17+173%65.7% | 6.1−57.3%39.5% | 14−59.2%54.7% | 35−26.2%78.7% | 47+72.3%62.2% | 27—81.2% | — | |
| Property, plant and equipment | 5.1−16.1%22.8% | 6.1−20.3%24.1% | 7.6−17.6%49.6% | 9.2+5.5%35.6% | 8.8+48.7%19.8% | 5.9−3.8%7.8% | 6.1—18.1% | — | |
| Right-of-use (leased) assets | 1.7−27.0%7.5% | 2.3+43.7%9.1% | 1.6−34.3%10.4% | 2.4—9.4% | — | — | — | — | |
| Long-term investments | — | — | 9.3−21.0%60.5% | 12+25.0%45.3% | 9.4−67.1%21.3% | 29+351%37.8% | 6.4—18.8% | — | |
| Non-current assets | 7.1−18.1%31.7% | 8.6−7.1%34.3% | 9.3—60.5% | — | — | — | — | — | |
| Total assets | 22−11.6%100% | 25+64.1%100% | 15−40.8%100% | 26−41.3%100% | 44−41.7%100% | 76+125%100% | 34—100% | — | |
| Accounts payable | 2.9+18.6%12.8% | 2.4+212%9.6% | 0.8−32.3%5.0% | 1.1−72.4%4.4% | 4.1+325%9.4% | 1.0−38.4%1.3% | 1.6—4.7% | — | |
| Debt due within a year | 1.0−85.4%4.4% | 6.8+69.5%26.9% | 4.0+241%26.0% | 1.2—4.5% | — | — | — | — | |
| Current liabilities | 7.7−39.0%34.7% | 13+74.0%50.3% | 7.3−14.8%47.4% | 8.6+5.9%32.9% | 8.1+181%18.3% | 2.9+11.6%3.8% | 2.6—7.6% | — | |
| Long-term debt | — | 0.6−90.1%2.5% | 6.4−15.8%41.5% | 7.6—29.2% | — | — | — | — | |
| Lease liabilities (non-current) | 0.6−49.3%2.9% | 1.3+49.0%5.1% | 0.9−26.9%5.6% | 1.2—4.5% | — | — | — | — | |
| Non-current liabilities | 3.6−26.0%16.1% | 4.9−52.3%19.3% | 10−12.1%66.2% | 12—44.6% | — | — | — | — | |
| Retained earnings | −302—−1352% | −267—−1060% | −238—−1550% | −214—−826% | −175—−395% | −132—−174% | −93—−276% | — | |
| Shareholders' equity | 11+42.8%49.2% | 7.7—30.5% | −2.1−136%−13.6% | 5.8−83.8%22.4% | 36−50.6%81.3% | 73—96.0% | −88—−260% | −82—— | |
| Total liabilities and equity | 22−11.6%100% | 25+64.1%100% | 15−40.8%100% | 26−41.3%100% | 44−41.7%100% | 76+125%100% | 34—100% | — | |
| Shares outstanding | 18+78.6%— | 10+516%— | 1.7+147%— | 0.7r20−96.4%— | 19+1.4%— | 18+3187%— | 0.6—— | — | |
| Cash-flow statement | |||||||||
| Share-based compensation | 4.9+71.9%— | 2.8−16.7%— | 3.4−21.3%— | 4.3−9.3%— | 4.8+3.8%— | 4.6+369%— | 1.0−1.9%— | 1.0—— | |
| Cash from operating activities | −28—— | −22—— | −17—— | −34—— | −32—— | −22—— | −17—— | −17—— | |
| Capital expenditure | −0.2—— | −0.1—— | −0.2—— | −1.8—— | −2.7—— | −0.8—— | −0.9—— | −3.1—— | |
| Cash from investing activities | −6.7—— | −0.3−109%— | 3.8−77.0%— | 17−55.1%— | 37—— | −41—— | −24−315%— | 11—— | |
| Debt issued | — | — | — | 12—— | — | — | — | — | |
| Debt repaid | −6.4—— | −3.3—— | −2.6—— | −0.4—— | — | — | — | — | |
| Shares issued | 0.5—— | — | 8.7+97.2%— | 4.4—— | — | — | — | — | |
| Cash from financing activities | 25−21.7%— | 32+225%— | 10.0−39.3%— | 16+1489%— | 1.0−98.4%— | 63+66.7%— | 38+301%— | 9.4—— | |
| Change in cash | −9.2−191%— | 10—— | −3.5—— | — | — | — | — | — | |
| Report | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2025 | $27 M | Private placement after listing | $10 to $50 million | 20 | equity, options | SEC |
| Dec 2024 | $15 M | Private placement after listing | $10 to $50 million | 12 | equity, options | SEC |
| Aug 2024 | $14 M | Private placement after listing | $10 to $50 million | 17 | equity, options | SEC |
| Jan 2024 | $35 M | Private placement after listing | $10 to $50 million | 20 | equity, options | SEC |
| Jun 2019 | $27 M | No. 2 | $10 to $50 million | 361 | equity, options | SEC |
| Feb 2016 | $8 M | No. 1 | $2 to $10 million | 8 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How PolyPid Ltd. compares in Biotechnology
- Market cap$103 M · higher than 36% of 726
- Price / book9.4× · lower than 16% of 534
- FCF yield-27.2% · higher than 36% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| PolyPid Ltd.🇮🇱 | $103 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at PolyPid Ltd.? Verify and update this profile — free
Show PolyPid Ltd.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.